Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus vs Investigator's Choice in Relapsed/Refractory MCL
NCT00117598Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of temsirolimus in mantle cell lymphoma (MCL) (3 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival up to 5 years. Started May 2005; status: completed.
02
Drugs
temsirolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00117598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117598.